Tags: glaxosmithkline plc | settles | unlawful | marketing

GlaxoSmithKline PLC Settles With States Over Unlawful Marketing

Image: GlaxoSmithKline PLC Settles With States Over Unlawful Marketing

By    |   Thursday, 05 Jun 2014 06:56 PM

GlaxoSmithKline PLC will settle with dozens of states, paying $105 million, after allegations that the company unlawfully marketed the asthma drug Advair and antidepressants Wellbutrin and Paxil.

Under the settlement announced Wednesday, the London-based pharmaceutical company also agreed to rules that bar it from paying doctors to promote its products; providing financial incentives that encourage salespeople to market drugs for unapproved uses; marketing drugs using results from inadequate studies or making unapproved claims that a product was "better, more effective, safer or has less serious side effects," according to a statement from California Attorney General Kamala D. Harris, The Associated Press reported.

Urgent: Do You Approve Or Disapprove of President Obama's Job Performance? Vote Now in Urgent Poll

California was among states whose attorneys general filed identical lawsuits in local courts. It will receive more than $7 million — the largest single portion of the settlement — after the deal is approved in San Diego County Superior Court.

The state lawsuits claimed that GlaxoSmithKline violated state consumer protection laws by misrepresenting the uses and qualities of the drugs and marketing them for purposes unapproved by the Food and Drug Administration — a practice called off-label marketing.

GlaxoSmithKline did not acknowledge any wrongdoing under the settlement, which is similar to one reached with the federal government in 2012 for a record $3 billion.

Its marketing practices also are under investigation in Britain, China and several other countries.

Nearly every big drugmaker has been prosecuted for off-label marketing and agreed to settlements with the government. Last year, Pfizer Inc. agreed to pay nearly $491 million to resolve an investigation into off-label marketing of the organ transplant drug Rapamune by a company Pfizer later acquired.

The GlaxoSmithKline settlement covers 44 states and the District of Columbia. It doesn't include Alaska, Louisiana, Mississippi, New Hampshire, South Carolina or West Virginia, although Louisiana previously settled its own suit.

GlaxoSmithKline said it already has put reforms in place.

Four years ago, GlaxoSmithKline committed to "stopping payments to doctors to speak about our products, stopping payments to doctors to attend medical conferences and cutting the tie linking the pay of our sales representatives who call on prescribers in the U.S. to the number of prescriptions issued," the company said in a statement. It said it was also rolling out such changes outside the U.S.

Urgent: Assess Your Heart Attack Risk in Minutes. Click Here.

© 2017 Newsmax. All rights reserved.

   
1Like our page
2Share
TheWire
GlaxoSmithKline PLC will settle with dozens of states, paying $105 million, after allegations that the company unlawfully marketed the asthma drug Advair and antidepressants Wellbutrin and Paxil.
glaxosmithkline plc, settles, unlawful, marketing
394
2014-56-05
Thursday, 05 Jun 2014 06:56 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved